Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis.

Sarcoma
Sheron LatchaCarlos D Flombaum

Abstract

Background. Pharmacokinetic data on clearance of ifosfamide in hemodialysis patients are limited. Consequently, these patients are excluded from therapy with this agent. We review the outcomes for patients at our institution with end stage renal disease on dialysis who received ifosfamide for metastatic sarcoma. Patients and Methods. We treated three patients with end stage renal disease on hemodialysis with escalating doses of ifosfamide. Data on radiographic response to therapy, WBC and platelet counts, signs or symptoms of infection, neuropathy and bladder toxicity are reported. Starting doses of ifosfamide were based on review of the literature available with subsequent modifications based on each patient's prior exposure to myelosuppressive agents and on symptoms of neurotoxicity and the degree of myelosuppression following each cycle of chemotherapy. Results. Myelosuppression was the most common side effect from therapy, but no patient developed a life threatening infection, neurotoxicity, or hematuria. One patient developed epistaxis in the setting of thrombocytopenia while on warfarin therapy. All patients had clinical evidence for therapeutic response and two had documented radiographic improvement following ifosfamide...Continue Reading

References

Jan 20, 1990·Lancet·L D Lewis, C A Meanwell
Sep 1, 1990·Cancer Treatment Reviews·H SauerM Blumenstein
Jul 1, 1986·European Journal of Cancer & Clinical Oncology·C A MeanwellG Blackledge
Mar 1, 1985·Cancer Treatment Reviews·W P BradeM Varini
Jun 1, 1994·Clinical Pharmacokinetics·T Wagner
May 1, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·R FiedlerB Osten
Oct 31, 2003·Oncology·M Furlanut, L Franceschi
Feb 8, 2008·The Journal of Bone and Joint Surgery. British Volume·A PradhanM Smith
Sep 6, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M SchlemmerJ Y Blay

❮ Previous
Next ❯

Citations

Nov 9, 2012·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Mohamad A CherryShubham Pant

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.